"Cyclohexanes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Six-carbon alicyclic hydrocarbons.
| Descriptor ID |
D003510
|
| MeSH Number(s) |
D02.455.426.392.368.367
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cyclohexanes".
Below are MeSH descriptors whose meaning is more specific than "Cyclohexanes".
This graph shows the total number of publications written about "Cyclohexanes" by people in this website by year, and whether "Cyclohexanes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclohexanes" by people in Profiles.
-
Pharmacokinetics and safety of maraviroc in neonates. AIDS. 2021 03 01; 35(3):419-427.
-
Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy. J Infect Dis. 2017 10 17; 216(7):813-818.
-
Differential CD4+ cell count increase and CD4+?: ?CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS. 2016 08 24; 30(13):2091-7.
-
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Na?ve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathog. 2016 Jan; 12(1):e1005381.
-
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. Clin Infect Dis. 2015 Oct 01; 61(7):1179-88.
-
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood. 2013 Jun 06; 121(23):4635-46.
-
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4? T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012 Aug 15; 206(4):534-42.